Kuros Biosciences Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Kuros Biosciences.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 42.2% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Kuros Biosciences AG's (VTX:KURN) 27% Share Price Plunge Could Signal Some Risk
Dec 13
Kuros Biosciences (VTX:KURN) Is In A Strong Position To Grow Its Business
Nov 28Kuros Biosciences AG's (VTX:KURN) Shares Climb 30% But Its Business Is Yet to Catch Up
Oct 24Market Participants Recognise Kuros Biosciences AG's (VTX:KURN) Revenues Pushing Shares 37% Higher
Aug 22We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Jul 16Kuros Biosciences AG (VTX:KURN) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
May 30Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge
Apr 11Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%
Jan 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Dec 17We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Sep 17Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues
Jun 28Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation
May 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Jun 11Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now
Apr 12Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years
Mar 02What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay
Nov 17
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kuros Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 53 | -9 | -3 | -2 | N/A |
| 3/31/2024 | 43 | -11 | -6 | -6 | N/A |
| 12/31/2023 | 34 | -14 | -9 | -9 | N/A |
| 9/30/2023 | 27 | -15 | -8 | -8 | N/A |
| 6/30/2023 | 20 | -16 | -8 | -7 | N/A |
| 3/31/2023 | 19 | -15 | -8 | -7 | N/A |
| 12/31/2022 | 18 | -15 | -8 | -7 | N/A |
| 9/30/2022 | 17 | -13 | -10 | -9 | N/A |
| 6/30/2022 | 15 | -11 | -12 | -11 | N/A |
| 3/31/2022 | 14 | -9 | -9 | -8 | N/A |
| 12/31/2021 | 14 | -8 | -6 | -5 | N/A |
| 9/30/2021 | 13 | -7 | -5 | -5 | N/A |
| 6/30/2021 | 12 | -6 | -5 | -5 | N/A |
| 3/31/2021 | 8 | -9 | -7 | -7 | N/A |
| 12/31/2020 | 4 | -12 | -9 | -9 | N/A |
| 9/30/2020 | 3 | -12 | -10 | -10 | N/A |
| 6/30/2020 | 3 | -12 | -10 | -10 | N/A |
| 3/31/2020 | 3 | -12 | -11 | -10 | N/A |
| 12/31/2019 | 3 | -11 | -11 | -11 | N/A |
| 9/30/2019 | 2 | -11 | -12 | -12 | N/A |
| 6/30/2019 | 1 | -12 | -13 | -12 | N/A |
| 3/31/2019 | 1 | -12 | -13 | -13 | N/A |
| 12/31/2018 | 1 | -12 | -13 | -13 | N/A |
| 9/30/2018 | 0 | -13 | -14 | -13 | N/A |
| 6/30/2018 | 0 | -15 | -14 | -12 | N/A |
| 3/31/2018 | 0 | -16 | N/A | -11 | N/A |
| 12/31/2017 | 1 | -16 | N/A | -11 | N/A |
| 9/30/2017 | 1 | -15 | N/A | -10 | N/A |
| 6/30/2017 | 1 | -13 | N/A | -10 | N/A |
| 3/31/2017 | 1 | -17 | N/A | -10 | N/A |
| 12/31/2016 | 1 | -20 | N/A | -9 | N/A |
| 9/30/2016 | 1 | -19 | N/A | -7 | N/A |
| 6/30/2016 | 1 | -18 | N/A | -6 | N/A |
| 3/31/2016 | 1 | -12 | N/A | -4 | N/A |
| 12/31/2015 | 0 | -6 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if KURN's forecast earnings growth is above the savings rate (0.3%).
Earnings vs Market: Insufficient data to determine if KURN's earnings are forecast to grow faster than the Swiss market
High Growth Earnings: Insufficient data to determine if KURN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if KURN's revenue is forecast to grow faster than the Swiss market.
High Growth Revenue: Insufficient data to determine if KURN's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KURN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 10:05 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kuros Biosciences AG is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Pfeifer-Rossi | Bank am Bellevue |
| Olav Zilian | Mirabaud Securities Limited |
| Dylan van Haaften | NIBC Bank N.V. |